Boehringer Ingelheim preps FDA submission with new data in rare pediatric lung disease
Ofev was one of Boehringer Ingelheim’s top sellers in the first half of this year, raking in a whopping $1.48 billion. Now the German pharma giant wants to expand into the small group of pediatric patients with lung scarring diseases.
Boehringer Ingelheim proved that a weight-based dosing regimen of Ofev, also known as nintedanib, in kids between 6 and 17 years old resulted in a dose exposure similar to adults, according to Phase III results released on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.